09-05-2008 07:08 PM CET - Politics, Law & Society
Print PDF

The Law Offices of James Sokolove Warns Consumers of Arthritis Drugs Linked to Serious Fungal Diseases

Press release from: LOJS

The Law Offices of James Sokolove (LOJS), dedicated to providing equal access to the civil justice system, sees the stricter medication guides now required by the Food & Drug Administration (FDA) on certain arthritis drugs as consumer critical. The FDA took action following the more than 200 reports that associated higher incidences of fungal infections, and even deaths, with the use of four tumor necrosis factor alpha blockers (TNF-alpha blockers) arthritis drugs.

“For the over 1 million Americans suffering from rheumatoid arthritis and facing chronic and debilitating pain, drugs, such as these, can help create normalcy in their daily lives,” says Attorney Jim Sokolove, founder of the LOJS. “While the FDA has responded here, consumers must remain highly vigilant themselves, so they can weigh the relief versus the risks imposed in using any drug.”

LOJS urges consumers with questions on the specific drugs involved to seek more information on the drug information portion of the FDA’s website and consult with their own physician.

About The Law Offices of James Sokolove
For almost 30 years, The Law Offices of James Sokolove (LOJS) has focused on reinventing how people obtain legal services. Equality of access, irrespective of ethnicity or income, and superior quality of representation and service within our civil justice system is our mission. Within an ever-changing legal profession, the LOJS business model is a proven success strategically matching specific client needs with particular law firm expertise and service quality. LOJS is the nation’s largest and fastest growing marketer of legal services. Additional information about The Law Offices of James Sokolove can be found at www.jimsokolove.com

The Law Offices of James Sokolove, LLC
1340 Centre Street
Newton, MA 02459
Ellen Fletcher
617 467 6967

This release was published on openPR.
News-ID: 52917
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: